Our aim was to describe the incidence, clinical course, and risk factors for idiopathic pneumonia syndrome (IPS) after high-dose chemotherapy with cyclophosphamide, carmustine, and thiotepa followed by autologous stem cell transplantation for high-risk breast cancer. Charts for patients who underwent high-dose chemotherapy for highrisk breast cancer at a single center from 1992 to 2000 were retrospectively reviewed, and potential risk factors for development of IPS were sought with the log-rank test. Of 164 patients reviewed, 20 developed IPS at a median onset of 87 days after the transplant (range, 2-257 days). The actuarial incidence of IPS in the first 100 days after the transplant was 8%, and 95% of patients developed symptoms within the first 6 months after transplant. Patient age, smoking status, breast cancer stage at diagnosis, and pretransplant lung function did not predict development of IPS. Three patients died of progressive pulmonary failure and the IPS resolved in the other 17. We concluded that IPS is an important cause of morbidity and mortality in patients with high-risk breast cancer undergoing high-dose chemotherapy. Given the absence of predictive factors, any pulmonary symptoms appearing in the first year after the transplant should be evaluated carefully. Bone Marrow Transplantation (2003) 31, 1157-1163. doi:10.1038/sj.bmt.1704141 Keywords: breast neoplasms; high-dose chemotherapy; autologous transplant; idiopathic pneumonia syndrome; carmustine The lung is a common site of toxicity after high-dose chemotherapy and autologous hematopoietic stem cell transplantation (AHSCT).
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The lung is a common site of toxicity after high-dose chemotherapy and autologous hematopoietic stem cell transplantation (AHSCT).
1 Pulmonary complications after AHSCT include opportunistic bacterial, viral, or fungal infections and treatment-related toxicity caused by chemotherapy or radiation. Pneumonia after AHSCT is common, and no infectious etiology can be found for 30-40% of cases of diffuse 'interstitial' pneumonia. 2 The term idiopathic pneumonia syndrome (IPS) reflects the broad definition and multifactorial etiology of this clinical syndrome. 3 IPS has been defined as 'evidence of widespread alveolar injury in the absence of active lower respiratory tract infection' after AHSCT, and bronchoalveolar lavage has been recommended as the primary diagnostic approach. 3 Characteristic histopathologic features of IPS include diffuse interstitial pneumonitis and alveolitis leading to interstitial fibrosis. 4, 5 Diffuse alveolar damage (DAD) is seen pathologically, although other patterns including organizing pneumonia with or without bronchiolitis obliterans and vascular damage have also been described. Patients classically present with an insidious onset of dry cough, dyspnea, hypoxemia, and multilobar radiographic infiltrates 40-75 days following transplantation. Exhaustive efforts to identify factors responsible for the development of IPS have been largely unsuccessful, although recent studies have implicated inflammatory cytokines in the pathogenesis of this syndrome. The etiology of IPS is likely multifactorial with varied clinical presentations, epidemiologies, and histopathologic correlates. Identification of risk factors for the development of IPS has been equally as elusive, in part owing to the inherent heterogeneity of this disorder. Increasing age, female sex, prior history of irradiation to the chest, patients with malignancy other than leukemia, and graft-versus-host disease have been reported as risk factors for the development of IPS, although the true role of these factors remains controversial. 3, [6] [7] [8] [9] Studies suggest that IPS represents the cumulative toxicities of pretransplant chemotherapy and radiation therapy on the lung. The diverse list of chemoradiotherapeutic protocols that are used as conditioning regimens prior to marrow transplantation may therefore underlie the inherent difficulty in characterizing IPS and identifying risk factors for the syndrome.
In the recent NHLBI workshop on IPS after AHSCT criteria for the diagnosis of IPS included widespread alveolar injury with (a) multilobar infiltrates on routine chest radiographs or chest computed tomography scans, (b) clinical symptoms and signs of pneumonia (dry cough, dyspnea, rales), (c) abnormal pulmonary physiology on arterial blood gas analyses or pulmonary function tests demonstrating a new or increased restrictive lung defect, and (d) absence of active lower respiratory tract infection on analysis of BAL fluid, transbronchial biopsy, or open lung biopsy. Fiberoptic bronchoscopy with bronchoalveolar lavage (BAL) may be the only diagnostic tool available in the post-transplant patient with diffuse lung infiltrates and prohibitive thrombocytopenia. BAL may offer information regarding evidence of infection, but does not provide histopathologic data regarding lung structural alterations in the work-up of IPS.
IPS has been reported in 4-28% of patients undergoing AHSCT. 6, 7, [10] [11] [12] [13] These studies, however, involved patients with a wide variety of diseases and chemotherapeutic regimens. The occurrence of IPS in the AHSCT patient is of particular intrigue because the incidence of certain viral infections including CMV is less infrequent, 14 and graftversus-host disease is presumably not relevant in this setting. Furthermore, the conditioning regimen is standardized, thus permitting a more valid assessment of risk factors including the drugs themselves in the development of this disorder. In autologous stem cell transplantation for hematologic or solid malignancies, two of the chemotherapeutic agents commonly used in the high-dose regimen, carmustine (BCNU) and cyclophosphamide, have been associated with pulmonary injury. In several studies, areaunder-the-curve analyses have demonstrated an association between lung injury in AHSCT and the dose and duration of exposure to carmustine. 15, 16 The incidence of pulmonary toxicity has been shown to increase with the total dose of carmustine. 17, 18 The incidence of IPS among patients with lymphoma treated with carmustine-containing high-dose chemotherapy followed by AHSCT has ranges from 5 to 47%, and is primarily affected by the dose of carmustine administered. 7, 19 In the treatment of high-risk breast cancer, various combinations of high-dose chemotherapeutic agents with or without carmustine have been investigated. 12 Ongoing randomized trials will define whether AHSCT has a role in the treatment of breast cancer at high risk of recurrence. A recent report of a trial by the Cancer and Leukemia Group B showed a transplant-related mortality rate of 7.8% for the treatment of high-risk breast cancer, and 35.5% of the deaths were because of pulmonary events. 20 These pulmonary events may have been related to the high doses of carmustine that were used (600 mg/m 2 over 3 days). The potential benefit of high-dose chemotherapy is an absolute survival difference of 10% compared with standard-dose chemotherapy. 21, 22 In the Pegase 01 trial, comparing high-dose chemotherapy followed by AHSCT vs no further chemotherapy in high-risk (N47) breast cancer patients, high-dose therapy improved the 3-year disease-free survival from 55-70.8% (Po0.003). 21 In another randomized study by Rodenhuis et al 22 including 289 patients with four or more positive axillary lymph nodes, the overall survival rates at 3 years were 79% in the standard-dose chemotherapy group and 89% in the highdose therapy plus AHSCT group, and the progression-free survival were 62 and 77% respectively. On the other hand, data from the American Blood and Marrow Transplantation Registry show that 2-3% of patients with high-risk primary breast cancer who undergo high-dose chemotherapy die within 100 days of AHSCT. To protect the potential survival benefit, ways of identifying and avoiding pulmonary toxicities, the most common lethal manifestation of toxicity after AHSCT, are needed. In this study, we reviewed a homogenous group of patients who underwent high-dose chemotherapy that included carmustine at 450 mg/m 2 over 3 days to clarify the incidence of IPS and its management. Specifically, the goal was to describe the incidence, clinical course, and risk factors for IPS among patients with high-risk breast cancer given high-dose chemotherapy consisting of cyclophosphamide, carmustine, and thiotepa followed by AHSCT at The University of Texas M. D. Anderson Cancer Center and to compare the findings with those previously reported.
Methods and materials

Study population
Using a computerized patient database, we identified patients with high-risk breast cancer who underwent highdose chemotherapy with cyclophosphamide, carmustine, and thiotepa followed by AHSCT at M. D. Anderson Cancer Center between October 1992 and December 2000. The treatment plans for these patients were approved by the Institutional Review Board of M. D. Anderson and all patients provided written informed consent. Clinical data were obtained from comprehensive chart reviews. Patient characteristics and data on previous treatments, disease status at AHSCT, and clinical, radiologic, and laboratory evidence of any pulmonary events were extracted and recorded.
Definitions of IPS
IPS was defined as evidence of widespread alveolar injury (multilobar infiltrates on chest radiography or computed tomography, with symptoms and signs of pneumonia and evidence of abnormal pulmonary physiology), absence of clinical or laboratory evidence of active lower respiratory tract infection (bacterial, fungal, viral, or parasitic), and absence of malignancy. 3 Patients who had no documented infection on BAL were classified as definite IPS. Patients who did not undergo bronchoscopy and had no evidence of infection on sputum culture were classified as probable IPS. The onset of IPS could occur at any time after initiating high-dose chemotherapy.
Conditioning regimen and supportive care
Patients were given cyclophosphamide, carmustine, and thiotepa as follows: cyclophosphamide, 2000 mg/m 2 i.v. over 24 h on days -7, -6, and -5 (total dose 6000 mg/m Infection prophylaxis consisted of acyclovir and fluconazole plus oral quinolones or a nonabsorbable antibiotic during neutropenic periods. Irradiated blood products were administered as needed to maintain a hemoglobin level of more than 8 g/dl and a platelet count of more than 10 Â 10 9 / l. No pre-emptive therapy for IPS such as steroids given with high-dose chemotherapy was envisaged.
Clinical course and outcome categories
Four outcome categories were defined for patients who met the criteria for IPS: 23 (1) resolution of pneumonia, that is, clearance of infiltrates with clinical and radiographic improvement; (2) recurrence of pneumonia, that is, improvement in radiographic infiltrates followed by recurrence of radiographic infiltrates and worsening or recurrence of signs and symptoms of pneumonia; (3) death from progressive respiratory failure, that is, deterioration in respiratory function leading to death; and (4) death from nonpulmonary causes without resolution of the pneumonia.
Statistical analysis
The probability of IPS was estimated by the Kaplan-Meier method. 24 Patients were censored at the time of death or at the time of last follow-up. Differences in the risk of IPS according to possible risk factors (age, smoking status, prior administration of radiation therapy to the chest, lung function before treatment, breast cancer stage at initial diagnosis) were evaluated by the log-rank test. The probability of nonrelapse mortality was defined as death from causes other than relapse of breast cancer and was estimated by the Kaplan-Meier method.
Results
Patient characteristics
During the study period, 164 patients with high-risk breast cancer who had undergone high-dose chemotherapy with cyclophosphamide, carmustine, and thiotepa followed by AHSCT were identified.. All patients were female and the median age was 46 years (range 22-63 years). At diagnosis, two patients had stage I disease, 16 stage IIA, 60 stage IIB, 56 stage IIIA, and 30 stage IIIB. Performance status at AHSCT was 0 for 96% of the patients. In all, 24 patients (14.6%) underwent AHSCT with bone marrow and 140 patients (85.4%) received peripheral blood stem cells. The median follow-up time after AHSCT was 44.3 months (range 0.1-105 months). A total of 111 patients (67.7%) had been given chest wall radiation before or after the AHSCT. Only 10 patients (6.1%) had radiation therapy before AHSCT. The timing of the radiation therapy posttransplant could not be identified on all patients and therefore its independent effect on the incidence of IPS could not be evaluated.
Incidence and presentation of IPS
Evaluation of clinical, radiologic, and laboratory data revealed that 20 patients (12%, 95% confidence interval (CI) 8-19%) met the criteria for having IPS. Negative findings on BAL cultures and cytology were used to establish the diagnosis of IPS among nine patients (45%) of the 20 patients. Among the remaining 11 patients, a presumptive diagnosis of IPS was made based on negative sputum microbial analyses. The estimated actuarial incidence of IPS in the first 100 days after the transplant was 8% (95% CI 5-13%) (Figure 1) . The median time at onset was 87 days (range 2-257 days), and 19 (95%) of the 20 patients who developed IPS showed symptoms within the first 6 months after transplant. Table 1 summarizes the characteristics and clinical presentation of patients with IPS. All patients presented with dyspnea, cough, or both and had evidence of multilobar pulmonary infiltration on chest X-ray or computed tomography. Of these, 10 patients also had fever at the time of presentation. Pulmonary function tests, carried out in seven patients, showed a reduction of the diffusion capacity of carbon monoxide of more than 25% relative to baseline levels before chemotherapy. Table 2 shows the results of the evaluation of potential risk factors. Patient age, smoking status, breast cancer stage at diagnosis, and measures of lung function before the transplant did not predict the development of IPS. These patients had been treated with various protocols before AHSCT using radiation and/or chemotherapy. No association has been demonstrated between IPS and treatment before AHSCT. There was a trend for increased risk with a smoking history, but this was not statistically significant. The impact of prior disturbances in lung function could not be assessed, as less than 10% of the patients had o80% predicted values for FEV and three of the 20 patients with IPS had unknown baseline pulmonary function data. In addition, the influence of prior chest wall irradiation before high-dose chemotherapy and AHSCT on the 
Risk factors for IPS
Clinical course of IPS
In total, 16 (80%) of the 20 patients with IPS received steroids for a median period of 2 weeks (range, 1 week to 6 months) as treatment for the IPS and nine of them received concurrent antimicrobial therapy. The remaining four patients received antimicrobial treatment alone. Overall, 17 patients (85%) had resolution of IPS and three patients (15%) died of progressive pulmonary failure. Autopsy was performed in one of the three patients and confirmed interstitial penumonitis compatible with carmustine toxicity and there was no evidence of malignancy. Among the three patients who died, all three were given the diagnosis of IPS based on negative BAL findings. Of the patients given steroids, 14 (87.5%) had resolution of IPS and two (12.5%) died of progressive pulmonary failure. Of the patients who did not receive steroids, three (75%) had resolution of IPS and one (25%) died of progressive pulmonary disease. No patients had recurrence of IPS. In this study, 12 of 164 patients died of causes unrelated to relapse, and the nonrelapse mortality rate at 1 year was 7% (95% CI 4-13%) (Figure 2 ). Therefore, IPS was the cause of transplant-related mortality in 25% (three of 12) cases.
Survival and relapse of breast cancer
Of the 164 patients (36%), 59 developed relapse of their breast cancer. The Kaplan-Meier estimated probabilities of overall and relapse-free survival for all 164 patients at the median follow-up of 44.3 months were 74.7 and 59.3% respectively.
Discussion IPS after AHSCT has several possible causes. High-dose chemotherapeutic agents, such as cyclophosphamide and carmustine that are used in conditioning regimens for hematopoietic stem cell transplantation, are known to cause pulmonary toxicity. Carmustine-related IPS appears to be dose-dependent, with a profound increase in the incidence of interstitial pneumonitis and pulmonary fibrosis observed at doses greater than 1500 mg/m 2 .
3,17 High-dose cyclophosphamide (7500 mg/m 2 ) has been reported to enhance the pulmonary toxicity of carmustine (400 mg/ m 2 ), 5 but the incidence of lung injury does not seem to be related to the area under the time/concentration curve for cyclophosphamide. 15, 16 Carmustine, at doses between 300 and 800 mg/m 2 , is commonly used in combination with other cytotoxic drugs in conditioning regimens for hematopoietic stem cell transplantation. In a dose-finding study, Wheeler et al 19 demonstrated that among patients treated with cyclophosphamide, carmustine, and etoposide for refractory lymphoma, 5% (two of 40 patients) developed IPS when carmustine 450 mg/m 2 was used, and 28% (five of 18 patients) had IPS when carmustine 600 mg/m 2 was administered. The number of deaths cause by IPS in the 600 mg/ m 2 group, 6%, was twice that in the 450 mg/m 2 group. In a dose-toxicity study of carmustine, etoposide, and melphalan chemotherapy followed by AHSCT for patients with hematologic malignancies, Ager et al 25 reported a significantly higher incidence of symptomatic pulmonary toxicity among patients given carmustine at 600 mg/m 2 than in patients given 450 mg/m 2 or 300 mg/m 2 . Rubio et al reported findings from another study of high-dose chemo-therapy (carmustine, melphalan, and etoposide) and AHSCT for patients with relapsed Hodgkin's disease. 7 The incidence of IPS was 15% in patients who were given less than 475 mg/m 2 carmustine, 32% when 475-525 mg/m 2 of carmustine was given, and 47% when more than 525 mg/m 2 of carmustine was administered. IPS-related mortality also increased with increasing dosages of carmustine and was 0, 12, and 26%, respectively, among the three different dosage groups. In that study, female gender was a risk factor for both the development of IPS and fatal outcome. The incidence of IPS in the dosage groups among females was 20% in the 475 mg/m 2 group, 44% in the 475-535 mg/m 2 group, and 87% in the more than 525 mg/m 2 group; the corresponding rates of fatal outcome were 0, 25, and 37%. This phenomenon has also been reported by others. 26, 27 Variations in the metabolism and pharmacokinetics of the drugs among different sexes have been suggested to explain these gender differences.
In our study population, all of whom were female, the incidence of IPS was 12%. A presumptive diagnosis of IPS was made in 11 patients who met the clinical criteria for IPS but did not have definitive testing done. Thus, our study may overestimate the true incidence of IPS. Most of our patients with IPS had resolution of clinical and radiologic abnormalities, and three patients (15%) had progression leading to respiratory failure and death. These findings are comparable to those previously reported for female patients with IPS who were given similar doses of carmustine. Given the small numbers of patients with IPS in our study, and the inherent difficulty in analyzing uncontrolled retrospective data, risk factors for this disorder could not be definitively established.
Pulmonary toxicity is an important cause of morbidity and mortality in patients undergoing high-dose chemotherapy and AHSCT, and reducing the pulmonary toxicity of the conditioning regimens may help to improve the prognosis and outcome for patients undergoing this type of treatment. Available data suggest that reductions in the dose of carmustine-based chemotherapeutic regimens in this setting may ameliorate rates of lung toxicity and improve patient outcomes. In our study all of the patients received a total of 450 mg/m 2 of carmustine. The 12.2% incidence of IPS in our study compares favorably with reports in the literature. Our findings may in fact overestimate the true incidence of IPS in our patient group, as in more than 50% of these patients a presumptive diagnosis of IPS was made. Further prospective studies are required to define the optimal dose of carmustine that offers maximal therapeutic benefit with minimal potential for lung injury. Along these lines, a prospective trial using carmustine at 300 mg/m 2 in high-dose chemotherapy for patients with high-risk primary breast cancer at our institution is planned.
In summary, the incidence of IPS among patients given cyclophosphamide, carmustine (450 mg/m 2 ), and thiotepa for high-risk breast cancer in this study was comparable to that reported in the literature. On the basis of the available data, it seems appropriate to reduce the dose of carmustine that is administered in preparation for hematopoietic stem cell transplantation. Reducing the toxicity of the conditioning regimen might help to improve the overall survival rate for patients undergoing AHSCT for high-risk breast cancer. Further studies are required to define the optimal high-dose chemotherapy regimen in this setting. 
